Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Influenza A virus H5N1 vaccine - Aramis Biotechnologies

Next Previous
Drug Profile

Influenza A virus H5N1 vaccine - Aramis Biotechnologies

Alternative Names: H5N1 avian influenza virus-like particle (VLP) vaccine - Medicago; H5N1 VLP vaccine - Medicago; MT-8972; One-dose H5N1 VLP vaccine - Medicago; Pandemic flu vaccine - Medicago; Plant-derived influenza vaccines - Medicago; Plant-made H5 VLP influenza vaccine - Medicago

Latest Information Update: 03 Aug 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Medicago
  • Developer Infectious Disease Research Institute; Medicago
  • Class Influenza A virus H5N1 vaccines; Viral vaccines; Virus-like particle vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II Influenza A virus H5N1 subtype

Most Recent Events

  • 03 Aug 2026 Phase-II development for Influenza A virus H5N1 subtype (Prevention) is ongoing in Canada (IM)
  • 01 Dec 2025 Mitsubishi Tanabe Pharma Corporation is now called Tanabe Pharma Corporation
  • 17 Feb 2023 Discontinued - Phase-I for Influenza A virus H5N1 subtype (Prevention) in USA (IM) (Mitsubishi Tanabe Pharma pipeline, February 2023)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top